JP2013518113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518113A5 JP2013518113A5 JP2012551255A JP2012551255A JP2013518113A5 JP 2013518113 A5 JP2013518113 A5 JP 2013518113A5 JP 2012551255 A JP2012551255 A JP 2012551255A JP 2012551255 A JP2012551255 A JP 2012551255A JP 2013518113 A5 JP2013518113 A5 JP 2013518113A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- optionally
- substituted
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- -1 pyridopyrazazinyl Chemical group 0.000 claims description 36
- 230000001404 mediated effect Effects 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Chemical group 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 229910052717 sulfur Chemical group 0.000 claims description 10
- 239000011593 sulfur Chemical group 0.000 claims description 10
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical group C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003725 azepanyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000005959 diazepanyl group Chemical group 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical group C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 125000005412 pyrazyl group Chemical group 0.000 claims description 4
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- FLUVVESHOANMOG-UHFFFAOYSA-N 1-cyclodecyldiazecane Chemical group C1CCCCCCCCC1N1NCCCCCCCC1 FLUVVESHOANMOG-UHFFFAOYSA-N 0.000 claims description 2
- JWGMXWNVAYWSNI-UHFFFAOYSA-N 1-cyclohexyldiazinane Chemical group C1CCCCC1N1NCCCC1 JWGMXWNVAYWSNI-UHFFFAOYSA-N 0.000 claims description 2
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical group C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 claims description 2
- WJWNYPADNFOIPT-UHFFFAOYSA-N 5-cycloheptyl-1,4-diazepane Chemical group C1CCCCCC1C1NCCNCC1 WJWNYPADNFOIPT-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 2
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 claims description 2
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 2
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims description 2
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N CN1CCNCCC1 Chemical compound CN1CCNCCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29866510P | 2010-01-27 | 2010-01-27 | |
| US61/298,665 | 2010-01-27 | ||
| PCT/US2011/022543 WO2011094288A1 (en) | 2010-01-27 | 2011-01-26 | Pyrazolopyrazine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518113A JP2013518113A (ja) | 2013-05-20 |
| JP2013518113A5 true JP2013518113A5 (https=) | 2014-03-13 |
Family
ID=43989802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551255A Pending JP2013518113A (ja) | 2010-01-27 | 2011-01-26 | ピラゾロピラジンキナーゼ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8895740B2 (https=) |
| EP (1) | EP2550272A1 (https=) |
| JP (1) | JP2013518113A (https=) |
| CN (1) | CN102869663A (https=) |
| AU (1) | AU2011209649A1 (https=) |
| CA (1) | CA2787079A1 (https=) |
| MX (1) | MX2012008641A (https=) |
| WO (1) | WO2011094288A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3046560B1 (en) * | 2013-09-18 | 2021-01-06 | EpiAxis Therapeutics Pty Ltd | Stem cell modulation ii |
| CN105837574B (zh) * | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853898A (en) | 1971-07-20 | 1974-12-10 | Sandoz Ag | 3-(2-substituted amino) pyridyl-phenyl ketone imines |
| US4988705A (en) | 1985-06-13 | 1991-01-29 | Schering Corporation | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives |
| FR2601015B1 (fr) | 1986-07-04 | 1988-08-05 | Rhone Poulenc Sante | Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE3827253A1 (de) | 1987-08-20 | 1989-03-02 | Sandoz Ag | Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen |
| CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
| US5100768A (en) | 1989-05-09 | 1992-03-31 | Kabushiki Kaisha Toshiba | Photosensitive composition |
| JPH03206450A (ja) | 1990-01-09 | 1991-09-09 | Fuji Photo Film Co Ltd | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法 |
| US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| JPH05331163A (ja) | 1991-03-26 | 1993-12-14 | Kumiai Chem Ind Co Ltd | ピリジン誘導体及び除草剤 |
| UA44220C2 (uk) | 1991-11-07 | 2002-02-15 | Агрево Юк Лімітед | Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами |
| US5476750A (en) | 1992-12-29 | 1995-12-19 | Hoechst Celanese Corporation | Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists |
| DE69404306T2 (de) | 1993-05-28 | 1997-10-30 | Pfizer | Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine |
| CA2133355A1 (en) | 1993-10-04 | 1995-04-05 | Itaru Nitta | Method for producing polypeptide |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| KR970705562A (ko) | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
| US5646330A (en) | 1995-02-17 | 1997-07-08 | Ciba-Geigy Corporation | Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| AU6748398A (en) | 1997-04-18 | 1998-11-13 | Kissei Pharmaceutical Co. Ltd. | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells |
| AU8033598A (en) | 1997-06-18 | 1999-01-04 | Nissan Chemical Industries Ltd. | Pyridine compounds and herbicides |
| US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
| US6225329B1 (en) | 1998-03-12 | 2001-05-01 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US20020115642A1 (en) | 2000-05-02 | 2002-08-22 | Chan Ming Fai | Beta-lactam antibiotics |
| AR029289A1 (es) | 2000-07-05 | 2003-06-18 | Ishihara Sangyo Kaisha | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo |
| DE10035908A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| PL362546A1 (en) | 2000-10-05 | 2004-11-02 | Fujisawa Pharmaceutical Co, Ltd. | Benzamide compounds as apo b secretion inhibitors |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| GB2373245A (en) | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US7101884B2 (en) * | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| MXPA04004178A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| JP2006507299A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害薬 |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| AP2005003365A0 (en) | 2003-02-07 | 2005-09-30 | Janssen Pharmaceutica Nv | Hiv inhibiting 1, 2, 4-triazines. |
| ES2305735T3 (es) | 2003-02-28 | 2008-11-01 | Schering Corporation | Biariltetrahidroisoquinolin-piperidinas como antagonistas del receptor de mch selectivos, para el tratamiento de obesidad y trastornos relacionados. |
| US20050203067A1 (en) | 2003-05-12 | 2005-09-15 | Hresko Michelle C. | Pesticidal compositions and methods |
| WO2005000813A1 (en) | 2003-05-30 | 2005-01-06 | Imclone Systems Incorporated | Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| DE602004031641D1 (de) | 2003-09-25 | 2011-04-14 | Janssen Pharmaceutica Nv | Die replikation von hiv hemmende purinderivate |
| EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| CA2545821C (en) | 2003-12-22 | 2010-09-21 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| AU2005219517A1 (en) * | 2004-02-27 | 2005-09-15 | F.Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
| TWI372624B (en) | 2004-03-30 | 2012-09-21 | Vertex Pharma | Azaindoles useful as inhibitors of jak and other protein kinases |
| KR20070002081A (ko) | 2004-04-02 | 2007-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌 |
| US20070275954A1 (en) | 2004-05-19 | 2007-11-29 | Astrazeneca Ab | Novel Fused Heterocycles and Uses Thereof |
| CN101389626A (zh) * | 2004-07-27 | 2009-03-18 | Sgx药物公司 | 稠环杂环激酶调节剂 |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US20090227799A1 (en) | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
| US7812166B2 (en) | 2004-10-29 | 2010-10-12 | Abbott Laboratories | Kinase inhibitors |
| EP1814883A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DE602006014502D1 (de) | 2005-01-14 | 2010-07-08 | Janssen Pharmaceutica Nv | Pyrazolopyrimidine als zellzyklus-kinasehemmer |
| DE602006012815D1 (de) | 2005-03-23 | 2010-04-22 | Hoffmann La Roche | Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten |
| US20060270709A1 (en) | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
| AU2006234627C1 (en) | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
| DE602006014540D1 (en) | 2005-05-16 | 2010-07-08 | Irm Llc | Pyrrolopyridinderivate als proteinkinaseinhibitoren |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| JP4946728B2 (ja) | 2007-08-23 | 2012-06-06 | 三菱電機株式会社 | 電力増幅器 |
| WO2009032653A1 (en) * | 2007-08-31 | 2009-03-12 | Smith Kline Beecham Corporation | Inhibitors of akt activity |
| CA2704266A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| CN102159574A (zh) * | 2008-07-23 | 2011-08-17 | 沃泰克斯药物股份有限公司 | 三-环吡唑并吡啶激酶抑制剂 |
| CA2767091A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
-
2011
- 2011-01-26 WO PCT/US2011/022543 patent/WO2011094288A1/en not_active Ceased
- 2011-01-26 MX MX2012008641A patent/MX2012008641A/es not_active Application Discontinuation
- 2011-01-26 AU AU2011209649A patent/AU2011209649A1/en not_active Abandoned
- 2011-01-26 CN CN2011800104433A patent/CN102869663A/zh active Pending
- 2011-01-26 CA CA2787079A patent/CA2787079A1/en not_active Abandoned
- 2011-01-26 EP EP11703959A patent/EP2550272A1/en not_active Withdrawn
- 2011-01-26 JP JP2012551255A patent/JP2013518113A/ja active Pending
-
2012
- 2012-07-27 US US13/560,122 patent/US8895740B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529066A5 (https=) | ||
| JP2011529062A5 (https=) | ||
| JP2011529065A5 (https=) | ||
| JP2011529063A5 (https=) | ||
| AU2018374456B2 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| JP6779371B2 (ja) | エンドソームＴｏｌｌ様受容体の阻害剤としての化合物および組成物 | |
| ES2982015T3 (es) | Derivados de piperidin-4-IL azetidina como inhibidores de JAK1 | |
| KR101785257B1 (ko) | 신규한 트리사이클릭 화합물 | |
| KR101391900B1 (ko) | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 | |
| DK3077395T3 (en) | PYRROLO [2,3-D] PYRIMIDINYL, PYRROLO [2,3-B] PYRAZINYL AND PYRROLO [2,3-D] PYRIDINYL ACRYLAMIDS | |
| JP7399968B2 (ja) | Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物 | |
| TWI866258B (zh) | 用於治療發炎性病症之新穎化合物及其醫藥組合物 | |
| US20110152243A1 (en) | Novel thienopyrrole compounds | |
| CN102711470A (zh) | 新的三环化合物 | |
| MX2013003913A (es) | Compuestos de furo [3, 2-d] pirimidina. | |
| TW201803871A (zh) | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 | |
| US20120330012A1 (en) | Novel Tricyclic Compounds | |
| JP2017511365A (ja) | 複素環キナーゼ阻害薬 | |
| US11213520B2 (en) | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | |
| JP2013518113A5 (https=) | ||
| TW202432556A (zh) | 5,6-稠合雙環雜芳族化合物 | |
| JP2013518114A5 (https=) | ||
| CN105142640B (zh) | 酪氨酸蛋白激酶抑制剂 | |
| CN112867715A (zh) | 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物 | |
| RU2011106786A (ru) | Ингибиторы пиразолопиридинкиназы |